254 related articles for article (PubMed ID: 18843862)
21. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
Isik AT; Bozoglu E; Naharci MI; Kilic S
Am J Geriatr Pharmacother; 2010 Oct; 8(5):454-9. PubMed ID: 21335298
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].
Schwalbe O; Wunderlich S; Kloft C
Med Monatsschr Pharm; 2006 Jun; 29(6):222-4. PubMed ID: 16792199
[TBL] [Abstract][Full Text] [Related]
24. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
Rockwood K; Fay S; Jarrett P; Asp E
Neurology; 2007 Apr; 68(14):1116-21. PubMed ID: 17404193
[TBL] [Abstract][Full Text] [Related]
25. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
Pirttilä T; Wilcock G; Truyen L; Damaraju CV
Eur J Neurol; 2004 Nov; 11(11):734-41. PubMed ID: 15525294
[TBL] [Abstract][Full Text] [Related]
28. Analyses of mortality risk in patients with dementia treated with galantamine.
Feldman HH; Pirttila T; Dartigues JF; Everitt B; Van Baelen B; Brashear HR; Berlin JA; Battisti WP; Kavanagh S
Acta Neurol Scand; 2009 Jan; 119(1):22-31. PubMed ID: 18518863
[TBL] [Abstract][Full Text] [Related]
29. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
Cossu G; Melis M; Melis G; Maccioni E; Putzu V; Catte O; Putzu PF
Mov Disord; 2004 Oct; 19(10):1243-4. PubMed ID: 15389998
[TBL] [Abstract][Full Text] [Related]
30. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
31. Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine.
Markowitz JS; Gutterman EM; Lilienfeld S; Papadopoulos G
Sleep; 2003 Aug; 26(5):602-6. PubMed ID: 12938815
[TBL] [Abstract][Full Text] [Related]
32. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
Haywood WM; Mukaetova-Ladinska EB
Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
[TBL] [Abstract][Full Text] [Related]
33. [Complete atrioventricular block during galantamine therapy].
Leentjens AF; Kragten JA
Ned Tijdschr Geneeskd; 2006 Mar; 150(10):563-6. PubMed ID: 16566422
[TBL] [Abstract][Full Text] [Related]
34. Effective pharmacologic management of Alzheimer's disease.
Farlow MR; Cummings JL
Am J Med; 2007 May; 120(5):388-97. PubMed ID: 17466645
[TBL] [Abstract][Full Text] [Related]
35. Sleep quality in patients with fibromyalgia using the Pittsburgh Sleep Quality Index.
Osorio CD; Gallinaro AL; Lorenzi-Filho G; Lage LV
J Rheumatol; 2006 Sep; 33(9):1863-5. PubMed ID: 16924687
[TBL] [Abstract][Full Text] [Related]
36. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
Tangwongchai S; Thavichachart N; Senanarong V; Poungvarin N; Phanthumchinda K; Praditsuwan R; Nidhinandana S; Chankrachang S
Am J Alzheimers Dis Other Demen; 2008 Dec-2009 Jan; 23(6):593-601. PubMed ID: 18845693
[TBL] [Abstract][Full Text] [Related]
37. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations.
Piotrovsky V; Van Peer A; Van Osselaer N; Armstrong M; Aerssens J
J Clin Pharmacol; 2003 May; 43(5):514-23. PubMed ID: 12751272
[TBL] [Abstract][Full Text] [Related]
38. The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease.
Dev H; Agius M; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):367-9. PubMed ID: 20562785
[TBL] [Abstract][Full Text] [Related]
39. Galantamine does not cause aggravated orthostatic hypotension in people with Alzheimer's disease.
van Beek AH; Sijbesma JC; Olde Rikkert MG; Claassen JA
J Am Geriatr Soc; 2010 Feb; 58(2):409-10. PubMed ID: 20370881
[No Abstract] [Full Text] [Related]
40. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
Gil-Néciga E; Gobartt AL;
Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
